BPL are pleased to share that we are in the May Issue of Manufacturing Today.
Manufacturing Today is one of the must-read trade publications for industry leaders. Through its print and digital publications and online presence, Manufacturing Today helps executives at the senior boardroom and production levels stay abreast of the most important operational issues in this dynamic market.
Manufacturing Today is all about championing the future for all manufacturers and their supply chains, addressing the needs of manufacturers and aims to help them today’s climate.
The article shares the history of BPL, from its infancy within the Lister Institute to our present form as part of BPL Holding Limited, giving readers an insight to the recent growth in international markets, the recently granted licence to market Albuminex® to China, and our first ever direct sales to Mexico.
The article also briefly explores our efficiency improvements, the recent US patent process for extracting Immunoglobulin and the works we have all done to improve yield across the business, the focus on training and our new aseptic process line (Line 4), finishing with our efforts to make BPL a great place to work, sharing our company values and the positive company culture we continue to create together.
You can read the full article here.
We are incredibly proud to be part of the 200th issue and would like to take this opportunity to thank everyone across the business, it is because of our colleagues tireless hard work that we have been recognised and the BPL story shared.
Donna Mitchell, BPL Communications Manager
About Bio Products Laboratory (BPL)
Recognising the importance of plasma and with many years of experience in the industry, BPL supplies high-quality plasma derived medicines to meet the needs of clinicians, patients, and customers globally. Headquartered in the United Kingdom, with US offices in Durham, NC, and plasma collection centres across the United States, we are dedicated to producing medicines for the treatment of immune deficiencies, bleeding disorders and infectious diseases as well for critical care. BPL invests in the latest R&D, technology and manufacturing methods, and continuously adapts to ensure that we continue to serve all our stakeholders effectively. For more information visit http://www.bplgroup.com or https://www.bpl-us.com.
BPL consists of two operating divisions — BPL Plasma and BPL Therapeutics. BPL Plasma, headquartered in Austin, Texas and operating in the USA, collects plasma from donors in around 28 centers across the U.S. BPL Plasma employs over 900 staff to support the needs of donors and to ensure high-quality plasma collection in all their centers. Plasma collection is regulated by both FDA and MHRA, and BPL Plasma follows industry guidelines. BPL Plasma operates plasma facilities, staffed with trained personnel, dedicated to supporting donors through the process that leads to the donation of plasma. Plasma is shipped to the headquarters of BPL Therapeutics in Elstree, United Kingdom. The plasma is fractionated, purified, and filled through the efforts of our over 1,000 employees involved in production, quality, R&D, commercial, customer services, and administrative activities. BPL’s plasma-derived medicines are commercially available in the U.K., USA, and 30 plus other countries around the world through our network of local affiliates and distribution partners.